XO Biologix markets MaviX, an amniotic-fluid product, as an unapproved new drug and unlicensed biologic.
What happened
FDA inspected XO Biologix's Austin, TX facility from January 3, 2024, to January 5, 2024, and reviewed the company's website and promotional material. FDA found MaviX, an amniotic fluid-derived product, promoted for pain, inflammation, and tissue regeneration and lacking an approved biologics license application (BLA), making it an unapproved new drug and unlicensed biological product. The letter also cites current good manufacturing practice (CGMP) violations at (b)(4) that make the product adulterated and says the labeling is false or misleading.
What FDA found
MaviX is an unapproved new drug because it is intended to treat disease or affect body function and has no approved drug application.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)MaviX is an unlicensed biological product because it is a biological product without an approved biologics license application (BLA).
section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1)MaviX is adulterated because manufacturing at (b)(4) did not meet current good manufacturing practice (CGMP) requirements, and XO Biologix remains responsible regardless of who made it.
section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B); 21 CFR parts 210 and 211MaviX is misbranded because its labeling is false or misleading: the instructions imply sheets when the product is a liquid solution, and expiry statements of five years and three years are unsupported by stability data.
section 502(a) of the FD&C Act, 21 U.S.C. § 352(a)FDA prohibits introducing MaviX into interstate commerce because it is an unapproved, adulterated, and misbranded drug.
section 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a), (d)
What FDA wants
FDA asks XO Biologix to respond in writing within 15 working days, outline steps taken or planned to fix the violations and prevent recurrence, and include supporting documentation. If the company cannot do so, it must explain the delay and give a completion timeframe.
Who should pay attention
- clinics and clinicians administering amniotic-fluid biologics
- companies marketing amniotic-fluid products as drugs
- contract manufacturers and packers of biologic products
This is a summary. Read the original letter on fda.gov.